Section of Cardiac Surgery, Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, Alberta, Canada.
Faculty of Medicine, Cumming School of Medicine, Calgary, Alberta, Canada.
J Card Surg. 2021 Apr;36(4):1480-1491. doi: 10.1111/jocs.15341. Epub 2021 Jan 21.
Heart failure is an increasingly prevalent medical condition associated with significant morbidity and mortality. In spite of optimal medical therapy, a large number of patients continue to deteriorate clinically and could potentially benefit from advanced therapies. While cardiac transplantation is an established therapy for end-stage heart failure, there are a limited number of donor hearts, and many patients may not be candidates. Over the past two decades, mechanical circulatory support and left ventricular assist devices (LVAD) have altered the heart failure management landscape. Herein we review the indications for LVAD implantation and how they have changed over time. We will also outline major technological evolutions in LVADs and summarize the landmark clinical trials pertaining to them. We also highlight the adverse events associated with LVADs and assess the limitations of the existing literature. Finally, we look ahead to the future of LVAD therapy for patients with advanced heart failure.
心力衰竭是一种日益流行的医学病症,与显著的发病率和死亡率相关。尽管采用了最佳的药物治疗,仍有大量患者的临床状况持续恶化,可能受益于先进的治疗方法。虽然心脏移植是治疗终末期心力衰竭的一种既定疗法,但供心数量有限,而且许多患者可能不符合移植条件。在过去的二十年中,机械循环支持和左心室辅助装置(LVAD)改变了心力衰竭的管理格局。本文综述了 LVAD 植入的适应证以及其随时间的变化。我们还将概述 LVAD 的主要技术进展,并总结与它们相关的标志性临床试验。我们还强调了与 LVAD 相关的不良事件,并评估了现有文献的局限性。最后,我们展望了先进心力衰竭患者的 LVAD 治疗的未来。